Mode
Text Size
Log in / Sign up

EUS-guided biliary drainage achieves higher technical and clinical success rates than balloon enteroscopy-assisted ERCPEUS-Guided Drainage Shows Higher Success for Biliary Obstruction

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that EUS-BD achieved higher technical and clinical success rates than BEA-ERCP in patients with surgically altered anatomy.

This meta-analysis evaluates the comparative efficacy of EUS-guided biliary drainage (EUS-BD) and balloon enteroscopy-assisted ERCP (BEA-ERCP) for managing malignant biliary obstruction (MBO) in patients with surgically altered anatomy (SAA). The analysis synthesized data from 394 patients in the BEA-ERCP group and 206 patients in the EUS-BD group.

The meta-analysis found that EUS-BD achieved a higher technical success rate of 97% compared to 75% for BEA-ERCP (RR 0.74; 95% CI, 0.67-0.82). Clinical success rates were also higher for EUS-BD at 92% compared to 72% for BEA-ERCP (RR 0.70; 95% CI, 0.61-0.80). No significant differences were observed between the two procedures regarding adverse event rates (11% for BEA-ERCP vs 17% for EUS-BD) or recurrent biliary obstruction (RBO) rates (26% for BEA-ERCP vs 23% for EUS-BD).

The authors note that these are preliminary findings derived from non-randomized studies. The evidence is limited by the lack of randomization and the preliminary nature of the data. While EUS-BD showed higher success rates in this analysis, the results are observational and do not establish definitive superiority.

How this fits prior evidence

This meta-analysis addresses a gap in comparing specific drainage techniques for malignant biliary obstruction in patients with surgically altered anatomy. While prior evidence established that metal stents provide longer time to recurrent biliary obstruction than plastic stents, and EUS-HGAS provides longer time to recurrent biliary obstruction than EUS-HGS, this study specifically compares the technical and clinical success rates of EUS-BD versus BEA-ERCP.

Researchers compared two different methods for treating malignant biliary obstruction in patients with surgically altered anatomy. The study looked at balloon enteroscopy-assisted ERCP and EUS-guided biliary drainage. These procedures are used to clear blockages in the bile ducts.

The results showed that EUS-guided drainage had a higher technical success rate of 97 percent compared to 75 percent for the balloon enteroscopy method. Clinical success was also higher for the EUS-guided approach at 92 percent, while the other method reached 72 percent. There was no significant difference found between the two methods regarding the rate of adverse events or the rate of recurring blockages.

Because these findings come from non-randomized studies, the results are considered preliminary. The data shows a link between the procedure type and success rates, but it does not prove one method is definitely better for everyone. Patients should talk to their doctors to decide which treatment is best for their specific medical situation.

What this means for you:
EUS-guided drainage showed higher success rates than balloon enteroscopy for certain biliary obstructions.

Common questions

How successful is EUS-guided biliary drainage?

The study found that EUS-guided biliary drainage had a technical success rate of 97 percent. In comparison, the balloon enteroscopy-assisted ERCP method had a technical success rate of 75 percent. These figures were based on a review of non-randomized data.

Are there more side effects with one treatment?

The study reported an adverse event rate of 17 percent for EUS-guided drainage and 11 percent for balloon enteroscopy-assisted ERCP. However, the difference between these two rates was not found to be statistically significant.

Does one method prevent the blockage from coming back?

The rate of recurrent biliary obstruction was 23 percent for the EUS-guided drainage group and 26 percent for the balloon enteroscopy-assisted ERCP group. This difference was not statistically significant, meaning both methods performed similarly regarding recurrence.

Study Details

Study typeMeta analysis
Sample sizen = 394
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
OBJECTIVES: This systematic review and meta-analysis evaluated the pooled outcomes and comparative evidence of balloon enteroscopy-assisted ERCP (BEA-ERCP) and EUS-guided biliary drainage (EUS-BD) for malignant biliary obstruction (MBO) in patients with surgically altered anatomy (SAA). METHODS: PubMed, Web of Science, and the Cochrane Library were searched up to January 2026. The primary outcome was the pooled technical success rate. Secondary outcomes included the clinical success rate, adverse event rate, recurrent biliary obstruction (RBO) rate, and mean procedure time. Subgroup analyses compared outcomes in studies directly comparing the two procedures. A random-effects model was used. RESULTS: Thirteen studies were included, comprising nine studies investigating BEA-ERCP (394 patients) and seven investigating EUS-BD (206 patients), including three comparative studies. Pooled technical and clinical success rates were 75% and 72% for BEA-ERCP and 97% and 92% for EUS-BD, respectively. Pooled adverse event rates were 11% for BEA-ERCP and 17% for EUS-BD, and pooled RBO rates were 26% and 23%, respectively. In subgroup analyses of the three comparative studies, technical success rates (risk ratio [RR], 0.74; 95% confidence interval [CI], 0.67-0.82) and clinical success rates (RR, 0.70; 95% CI, 0.61-0.80) were significantly lower with BEA-ERCP than with EUS-BD, with no significant differences in adverse event rates, RBO rates, or procedural times. CONCLUSION: In the three comparative studies, EUS-BD achieved higher technical and clinical success rates than BEA-ERCP for MBO in patients with SAA, with no significant difference in adverse events. These non-randomized findings are preliminary, and large-scale prospective comparative studies are warranted.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.